Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.

Soleno Therapeutics Inc.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on GE Healthcare Technologies Inc (GEHC – Research Repo...

Analysts Offer Insights on Healthcare Companies: GE Healthcare Technologies Inc (GEHC) and Soleno Therapeutics (SLNO)

Soleno Therapeutics ( ($SLNO) ) just unveiled an announcement. On January 21, 2026, Soleno Therapeutics’ board, following a review by its independe...

Soleno Therapeutics Updates Executive Compensation and Severance Plans

In a report released today, Derek Archila from Wells Fargo maintained a Buy rating on Soleno Therapeutics, with a price target of $106.00. Accordin...

Soleno Therapeutics (SLNO) Receives a Buy from Wells Fargo

In a report released yesterday, Derek Archila from Wells Fargo maintained a Buy rating on Soleno Therapeutics, with a price target of $106.00. The ...

Current Yield	N/A	Payout Ratio	0.00%
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SLNO	$44.10	+4.21%	1.33M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SLNO	$44.10	+4.2%	1.33M
3
4
5
6

SLNO

SLNO

Dividend Overview

Get Soleno Therapeutics Inc. Data in Excel

Get Soleno Therapeutics Inc. Data in Excel